121 related articles for article (PubMed ID: 1531714)
1. Flow-cytometric monitoring of ATG therapy for steroid-resistant rejection.
Clark KR; Forsythe JL; Shenton BK; Lennard TW; Proud G; Taylor RM
Transplant Proc; 1992 Feb; 24(1):315. PubMed ID: 1531714
[No Abstract] [Full Text] [Related]
2. In vivo-in vitro correlates of human rejection using flow cytometry with two-color fluorescence on peripheral blood mononuclear cells.
Gross U; Thomas F; Matthews C; Thomas J; Cunningham P; Ritter T
Transplant Proc; 1987 Feb; 19(1 Pt 2):1609-10. PubMed ID: 2978885
[No Abstract] [Full Text] [Related]
3. Diagnosis of renal allograft rejection by analysis of infiltrating cell profiles: an assessment of cyclosporine, azathioprine/prednisolone, and triple therapy.
McWhinnie DL; Azevedo LS; Carter NP; Cranston D; Jones R; Wood RF; Morris PJ
Transplant Proc; 1987 Feb; 19(1 Pt 2):1633-4. PubMed ID: 3152633
[No Abstract] [Full Text] [Related]
4. Rapid T cell recovery after prophylactic ALG is associated with pancreas allograft rejection.
Munn SR; Perkins JD
Transplant Proc; 1990 Apr; 22(2):619. PubMed ID: 2139264
[No Abstract] [Full Text] [Related]
5. Induction immunosuppression with antithymocyte globulin in renal transplantation using a variable dose according to the absolute number of CD3+ T cells.
Abouna GM; Kumar MS; al-Abdullah IH; Loose J; Sullivan DK; Phillips K; Yost S; Seirka D
Transplant Proc; 1995 Oct; 27(5):2676-8. PubMed ID: 7482872
[No Abstract] [Full Text] [Related]
6. CD5-T lymphocytes in renal transplant recipients.
McKay PJ; Kyle B; McLaren A; McMillan MA; Lucie NP
Clin Lab Haematol; 1991; 13(4):335-40. PubMed ID: 1723035
[TBL] [Abstract][Full Text] [Related]
7. Sequential monitoring of immunoregulatory T cell subsets in renal transplantation.
Mestre M; González C; Griño JM; Valls A; Bonete J; Mané E; Corominas M; Bas J; Romeu A; Buendia E
Transplant Proc; 1992 Feb; 24(1):73-5. PubMed ID: 1539351
[No Abstract] [Full Text] [Related]
8. Monitoring of ATG therapy by flow cytometry and lymphocyte counts in renal transplantation.
Buchler M; Thibault G; al Najjar A; Valentin JF; Guerraoui A; Nivet H; Bardos P; Lebranchu Y
Transplant Proc; 1996 Oct; 28(5):2817-8. PubMed ID: 8908076
[No Abstract] [Full Text] [Related]
9. Flow cytometric measurements in 104 anti-T-lymphocyte globulin treatments.
Ekberg H; Persson NH; Olsson M; Lundell A; Bredberg A
Transplant Proc; 1992 Dec; 24(6):2551-2. PubMed ID: 1465863
[No Abstract] [Full Text] [Related]
10. Degree of modulation of cell-surface CD3 by anti-lymphocyte therapies.
Henell KR; Bakke A; Kenny TA; Kimball JA; Barry JM; Norman DJ
Transplant Proc; 1991 Feb; 23(1 Pt 2):1070-1. PubMed ID: 1824886
[No Abstract] [Full Text] [Related]
11. Differential effects of antilymphocyte globulins on lymphocytic molecules (E2 and CD2) implicated in the rosette phenomenon.
Cassuto-Viguier E; Ticchioni M; Bernard-Pomier G; Zoccola D; Mondain JR; Barrillon D; Bernard A
Transplant Proc; 1993 Jun; 25(3):2322-4. PubMed ID: 8100094
[No Abstract] [Full Text] [Related]
12. Comparative flow cytometric analysis of peripheral blood, graft infiltrating and urinary sediment cells during kidney allograft rejection.
Ciniti P; Evangelista B; Speziale A; Ingenito L; Orlandini AM; Baiano V; Renna Molajoni E; Cortesini R
Transplant Proc; 1995 Feb; 27(1):919-21. PubMed ID: 7879229
[No Abstract] [Full Text] [Related]
13. Predictive value of IgG subclass levels for infectious complications in renal transplant recipients.
Wieneke H; Otte B; Lang D; Heidenreich S
Clin Nephrol; 1996 Jan; 45(1):22-8. PubMed ID: 8616953
[TBL] [Abstract][Full Text] [Related]
14. HLA-DR matching is effective in reducing posttransplant costs in renal allograft recipients on triple therapy.
Taylor CJ; Bayne AM; Welsh KI; Morris PJ
Transplant Proc; 1993 Feb; 25(1 Pt 1):210-1. PubMed ID: 8438273
[No Abstract] [Full Text] [Related]
15. Contribution of T-cell subset monitoring of renal transplant recipients in the cyclosporine era.
Khanuja PS; Toledo-Pereyra LH; Gordon DA; Bandlien KO; Whitten JI
Transplant Proc; 1989 Feb; 21(1 Pt 2):1852-3. PubMed ID: 2652602
[No Abstract] [Full Text] [Related]
16. OKT3 for steroid-resistant renal allograft rejection: differential response in adults and children.
Shmueli D; Nakache R; Lustig S; Bar Nathan N; Yussim A; Shaharabani E; Geier A; Shapira Z
Transplant Proc; 1994 Aug; 26(4):1948-9. PubMed ID: 8066630
[No Abstract] [Full Text] [Related]
17. Treatment of steroid resistant rejection following renal transplantation: benefits and risks of OKT3 therapy.
Kehinde EO; Feehally J; Scriven SD; Veitch PS; Bell PR
Transplant Proc; 1996 Jun; 28(3):1449-50. PubMed ID: 8658735
[No Abstract] [Full Text] [Related]
18. Inducible IL-2 on CD8 lymphocytes as a postoperative predictor of rejection in renal allograft recipients.
Langley J; Dickerman R; Vergne-Marini P; Williams J; Jensik S; Kenyon N; Anderson J
Transplant Proc; 1993 Feb; 25(1 Pt 2):939-43. PubMed ID: 8442275
[No Abstract] [Full Text] [Related]
19. Induction therapy including antithymocyte globulin induces marked alterations in T lymphocyte subpopulations after liver transplantation: results of a long-term study.
Oertel M; Sack U; Kohlhaw K; Lehmann I; Emmrich F; Berr F; Hauss J; Schwarz R
Transpl Int; 2002 Oct; 15(9-10):463-71. PubMed ID: 12389078
[TBL] [Abstract][Full Text] [Related]
20. Randomized clinical trial of antithymocyte globulin induction in renal transplantation comparing a fixed daily dose with dose adjustment according to T cell monitoring.
Abouna GM; al-Abdullah IH; Kelly-Sullivan D; Kumar MS; Loose J; Phillips K; Yost S; Seirka D
Transplantation; 1995 Jun; 59(11):1564-8. PubMed ID: 7778170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
